期刊文献+

EV71病毒P1和3CD基因共表达重组杆状病毒双顺反子穿梭载体的构建及鉴定

Construction and identification of recombinant baculovirus transfer co-expression vector of P1 and 3CD genes from EV71
下载PDF
导出
摘要 目的通过克隆EV71病毒结构前体蛋白P1和非结构蛋白3CD,构建共表达P1前体蛋白和非结构蛋白3CD的重组杆状病毒表达载体。方法设计合成EMCV病毒IRES序列的特异性引物,克隆至含有CMV启动子的杆状病毒穿梭载体pFastBacDual-CMV上,命名为pFBCMV-IRES。从手足口病重症患者分离EV71病毒株,经RT-PCR技术分别扩增出EV71病毒的P1前体蛋白区与3CD区的片段,定向克隆至杆状病毒穿梭载体pF-BCMV-IRES的IRES序列的上游和下游,随后转化到大肠杆菌DH5α中,经PCR和双酶切鉴定转化菌落。结果通过对重组杆状病毒穿梭载体pFBCMV-IRES-P1-3CD进行酶切和DNA序列分析,证明共表达EV71病毒P1和3CD基因的重组杆状病毒双顺反子穿梭载体构建成功。结论共表达EV71病毒P1和3CD基因重组杆状病毒双顺反子穿梭载体的成功构建,将为下一步制备EV71病毒的类病毒颗粒疫苗打下基础。 Objective To amplify P1 and 3CD genes from patient infected with EV71 and to construct the recom- binant baculovirus transfer co- expression vector of P1 and 3CD. Methods The internal ribosomal entry site (IRES) from encephalomyocarditis virus (EMCV) was amplified and inserted into pFastBacDual vector containing CMV promoter, named pFBCMV - IRES. The cDNA encoding P1 and 3CD were obtained by RT - PCR from EV71 isolated from patient and recombined into pFBCMV -IRES vector. The reconstructed plasmid pFBCMV -IRES -P1 -3CD was confirmed by restriction enzymolysis and PCR. Results The co - expression plasmid pFBCMV - IRES - P1 - 3CD was successfully constructed, which were further confirmed with PCR and double endonucleases. Conclusion The successful construction of recombinant baculovirns transfer vector pFBCMV - IRES - P1 - 3CD establishes experimental basis for construction of virus like particle vaccine of EV71.
出处 《广东医学》 CAS CSCD 北大核心 2012年第18期2725-2727,共3页 Guangdong Medical Journal
基金 广东省医学科研基金资助项目(编号:B2010287) 广东省深圳市罗湖区软科学研究计划项目(编号:2010069)
关键词 肠道病毒71型 杆状病毒 类病毒颗粒 疫苗 enterovirns 71 baculovirus virus like particles vaccine
  • 相关文献

参考文献9

  • 1YI L, LU J, KUNG H F, et al. The virology and developments to- ward control of human enterovirus 71 [J]. Crit Rev Microbiol, 2011, 37(4) : 313 -327.
  • 2DE W, CHANGWEN K, WEI L. A large outbreak of hand, foot, and mouth disease caused by EV71 and CAVI6 in Guangdong, China, 2009[J]. Arch Virol, 2011, 156(6) : 945 -953.
  • 3WU C N, LIN Y C, FANN C, et al. Protection against lethal en- terovirus 71 infection in newborn mice by passive immunization with subunit VPI vaccines and inactivated virus [ J ]. Vaccine, 2001,20(5/6) : 895 -903.
  • 4LIU F, GE S, LI L, et al. Virus -like particles: potential veterinary vaccine immunogens[J]. Res Vet Sci, 2011,93(2) : 533 -539.
  • 5YANG C, YE L, COMPANS R W. Protection against filovirus in- fection : virus - like particle vaccines [ J ]. Expert Rev Vaccines, 2008, 7 (3) 333 - 334.
  • 6MCMINN P C. An overview of the evolution of enterovirus 71 and its clinical and public health significance [ J ]. FEMS Microbiol Rev, 2002, 26( 1 ) : 91 - 107.
  • 7CHUNG Y C, HO M S, WU J C, et al. Immunization with virus- like particles of enterovirus 71 elicits potent immune re- sponses and protects mice against lethal challenge[ J ]. Vaccine, 2008, 26(15) : 1855 - 1862.
  • 8CHUNG C Y, CHEN C Y, LIN S Y, et al. Enterovirus 71 virus - like particle vaccine: improved production conditions for enhanced yield[J]. Vaccine, 2010, 28(43): 6951 -6957.
  • 9LJUBOJEVIC S. The human papillomavirus vaccines [ J]. Acta Dcrmatovenerol Croat, 2006, 14(3): 208.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部